TY - JOUR
T1 - Raltegravir, maraviroc, etravirine
T2 - An effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience
AU - Nozza, Silvia
AU - Galli, Laura
AU - Visco, Francesca
AU - Soria, Alessandro
AU - Canducci, Filippo
AU - Salpietro, Stefania
AU - Gianotti, Nicola
AU - Bigoloni, Alba
AU - Torre, Liviana Della
AU - Tambussi, Giuseppe
AU - Lazzarin, Adriano
AU - Castagna, Antonella
PY - 2010/3
Y1 - 2010/3
N2 - We prospectively evaluated 28 triple-class experienced HIV-1-infected patients harbouring R5 virus, who received maraviroc, raltegravir and etravirine. By on-treatment analysis, 26 (92%) had less than 50 copies HIV-RNA/ml at week 48. The median (interquartile range) 48-week increase in CD4 cell counts was 267 (136-355) cells/μl. Three serious adverse events occurred: one recurrence of mycobacterial spondylodiscitis, one anal cancer, one Hodgkin lymphoma. Although long-term safety needs further study, this protease inhibitor and nucleoside analogue-sparing regimen showed sustained efficacy.
AB - We prospectively evaluated 28 triple-class experienced HIV-1-infected patients harbouring R5 virus, who received maraviroc, raltegravir and etravirine. By on-treatment analysis, 26 (92%) had less than 50 copies HIV-RNA/ml at week 48. The median (interquartile range) 48-week increase in CD4 cell counts was 267 (136-355) cells/μl. Three serious adverse events occurred: one recurrence of mycobacterial spondylodiscitis, one anal cancer, one Hodgkin lymphoma. Although long-term safety needs further study, this protease inhibitor and nucleoside analogue-sparing regimen showed sustained efficacy.
UR - http://www.scopus.com/inward/record.url?scp=77949551533&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77949551533&partnerID=8YFLogxK
U2 - 10.1097/QAD.0b013e3283372d76
DO - 10.1097/QAD.0b013e3283372d76
M3 - Article
C2 - 20154578
AN - SCOPUS:77949551533
VL - 24
SP - 924
EP - 928
JO - AIDS
JF - AIDS
SN - 0269-9370
IS - 6
ER -